Diabetes statistics around the world in 2021

Diabetes diagnostics systems are used to measure blood glucose levels or blood sugar levels, which indicates whether or not a person is suffering from diabetes. According to International Diabetes Federation’s findings in 2021. 537 million adults (20-79 years) are living with diabetes 1 in 10. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries. Diabetes is responsible for 6.7 million deaths in 2021, 1 every 5 seconds. Diabetes caused at least USD 966 billion in health expenditure 316% increase over the last 15 years. 541 million adults have Impaired Glucose Tolerance (IGT), which places them at high risk of type 2 diabetes. IDF analyzed by regional investigation, that adults are living with diabetes also future predictions in 2030 and 2045.Table 1.

Table 1.The number of adults living with diabetes and upcoming numbers.

HbA1c testing review

Demand for diabetes diagnostics devices and systems is being driven by the need for easier, economic, and efficient management of the global diabetes epidemic, improving ease-of-use and accuracy of devices, and development of non-invasive techniques to simplify regular glucose testing. The spread of diabetes at epidemic proportions is driving the requirement for pre-diabetics testing and post-prandial glucose-level monitoring. With increasing levels of patient education on possible ways of preventing and delaying the onset of Type II diabetes, more and more pre-diabetics are expected to start testing blood glucose. Technology advancements in diabetes diagnostics that are poised to benefit market prospects in the near term include mHealth Solutions for diabetes diagnosis; wearable glucose testing devices; implantable continuous glucose monitor; and cloud-enabled CGM devices, among others.

COVID-19 and diabetes

There are many reasons why people with diabetes may be more susceptible to developing adverse events following COVID-19 infection. Diabetes is extremely common in older populations, including those living in long-term care facilities, a setting that was particularly affected byearly outbreaks of COVID-19 severity and death. As in thegeneral population, age appears to be an important riskfactor for COVID-19 severity and mortality in hospitalized people with diabetes. Research studies suggest that diabetes is a risk factor for severe COVID-19-related disease, resulting in a greater risk of hospitalization and death. Populations with diabetes should be considered a high priority when considering measures to reduce COVID-19 infection and its consequences.

By 2026, the global diabetes diagnostics market will total $42.4 billion

According to Research and Markets, the world’s largest market research store. Reports in February 2022 that amid the COVID-19 crisis, the global market for Diabetes Diagnostics estimated at US$26.5 Billion in the year 2020, is projected to reach a revised size of US$42.4 Billion by 2026, growing at a compound annual growth rate (CAGR) of 8.1% over the analysis period.

Test Strips, one of the segments analyzed in the report, is projected to record an 8.3% CAGR and reach US$11.3 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Lancets segment is readjusted to a revised 7.5% CAGR for the next 7-year period.

Blood glucose test strips are small disposable strips of plastic that enable people with diabetes to measure and monitor their blood sugar levels at home. Each test strip is a laminate of plastic and chemicals that provides a single-use diagnostic test for measuring blood sugar. Persistent growth in the blood glucose test strips market has been driven to a greater extent by an increase in the number of diabetics, and by technological innovations.

Blood sugar lancets play a vital role in the early detection of diabetes. The rising prevalence of diabetes, favorable reimbursement policies in developed countries, rising geriatric population, continuous technological advancements, and faster product approvals are some of the key factors spurring demand.

References

1 World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 – 11 March 2020. WHO: May 11, 2020.Available from: https://www.who.int/director-general/speeches/detail/who-director-generals-opening-remarks-at-the-media-briefing-on-covid-19-11- March 2020?

2 Wu C, Chen X, Cai Y. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13; 180(7):934-943; DOI:10.1001/ jamainternmed.2020.0994

3 Hu Y, Sun J., Dai Z, Deng H, Li X, Huang Q. Prevalence, and severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Virol. 2020 Jun; 127:104371. DOI: 10.1016/j.jcv.2020.104371

4 Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and metaregression. Diabetes Metab Syndr. 2020 Jul-Aug; 14(4):395- 403. Epub 2020 April 17. DOI: 10.1016/j.dsx.2020.04.018

5       Zhang Y, Cui Y, Shen M, Zhang J, Liu B, Dai M et al. Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study. Diabetes Res Clin Pract. 2020 May 22; (165); DOI: 10.1016/j.diabres.2020.108227